In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …

Colorectal cancer (CRC) is the second most common cause of cancer death in the United
States. Every 3 years, the American Cancer Society provides an update of CRC statistics …

Liver cancers are the fourth leading cause of cancer-related mortality worldwide. In the past
decade, breakthroughs in the field of artificial intelligence (AI) have inspired development of …

Oncologists face increasingly complex clinical decision-making processes as new cancer
therapies are approved and treatment guidelines are revised at an unprecedented rate. With …

Certain genetic alterations and right-sided primary tumor location are associated with
resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer …

Background Contemporary management of patients with synchronous colorectal cancer and
liver metastases is complex. The aim of this project was to provide a practical framework for …

Clinical hyperthermic intraperitoneal chemotherapy (HIPEC) is regarded as a potential
treatment that can prolong survival of patients with peritoneal metastases after cytoreductive …

PURPOSE To verify whether both doublet chemotherapy with a modified schedule of
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) and monochemotherapy with …

BACKGROUND Improving and predicting tumor response to immunotherapy remains
challenging. Combination therapy with a transforming growth factor-β receptor (TGF-βR) …